![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, April 24, 2024 9:01:50 AM
Even if you assume it takes the entire OS of 2 billion shares to satisfy all warrants and notes outstanding.... essentially fully diluted.. Probably wont be near that much...
.02 would be a 40 million mrkt cap
.08 would be a 160 million mrkt cap
Considering they have an OSA program supposedly "valued" around 20 million, that assuming they are completeing some preclinical work on the new formulations in preps to launch human trials in late stages. And their promising SCI/ADHD candidate is waiting funding to continue human trials in later stages as well.
And then the pain/epilepsy candidate progressing through NIH preclinicals, which if successful as they appear confident in, would open up grant funding for human trials. Which would then be a high profile candidate that could help mitigate opioids. I've seen other preclinical pharma deals in the 10's to hundreds of million upfront, with potential milestone payments dwarfing that. Feels just like accumulating at pennies on the dollar here. But for balance, there is still plenty of risk in pharma industry, huge thresholds have to be met to advance any drug candidate. And maybe that is just simply where this is at currently. Insiders and institutional according to filings appear to be lining up with equity positions that can possibly pay off massively if their drug candidates successfully advance. Success not guaranteed but if it happens, I think we all can imagine how quickly the stock will gain traction and become one of those OTC story stocks... IMO
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:05:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 12:52:24 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM